CytRx Corporation Regains Full Compliance With Nasdaq Listing Requirements

LOS ANGELES, Jan. 4 /PRNewswire-FirstCall/ -- CytRx Corporation , a biopharmaceutical company engaged in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi), today announced that it has regained full compliance for continued listing on the Nasdaq Capital Market (formerly the Nasdaq SmallCap Market) by satisfying the $1.00 minimum bid price requirement for 10 consecutive market trading days in accordance with Marketplace Rule 4310(c)(4).

As background, on June 7, 2005, CytRx received notification from the Nasdaq Stock Market informing CytRx that for the prior 30 consecutive business days the bid price of the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq SmallCap Market under Marketplace Rule 4310(c)(4). The notice stated that under Marketplace Rule 4310(c)(8)(D), the Company would be provided with 180 calendar days, or until December 5, 2005, to regain compliance with Marketplace Rule 4310(c)(4). On December 5, 2005, CytRx was provided with an additional 180 calendar day period to demonstrate compliance. The additional time period was provided by the Nasdaq Stock Market based on the fact that the Company met all Nasdaq Capital Market initial inclusion criteria set forth in Marketplace Rule 4310(c) other than the bid price requirement. Since then, the closing bid price of CytRx’s common stock has been at $1.00 per share or greater for more than 10 consecutive market trading days.

“We are pleased to regain full compliance with the Nasdaq listing requirements, and we see this as a solid first step in what promises to be an exciting year at CytRx,” said Steven A. Kriegsman, CytRx’s President and CEO.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi). The Company owns three clinical-stage compounds based on its small molecule “molecular chaperone” co-induction technology, as well as a targeted library of 500 small molecule drug candidates that may be used to screen for new drug candidates. CytRx has initiated a Phase II clinical trial with its lead small molecule product candidate arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Arimoclomol has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration. CytRx has previously announced that a novel HIV DNA + protein vaccine exclusively licensed to CytRx and developed by researchers at the University of Massachusetts Medical School (UMMS) and Advanced BioScience Laboratories, and funded by the National Institutes of Health, demonstrated very promising interim Phase I clinical trial results that indicate its ability to produce potent antibody responses with neutralizing activity against multiple HIV viral strains. For more information, visit CytRx’s Web site at www.cytrx.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to the expected timing, scope and results of our clinical development and research programs, including the initiation of clinical trials, and statements regarding the potential benefits of our drug candidates and potential drug candidates. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding our continued compliance with Nasdaq listing requirements, uncertainties related to regulatory approvals for clinical testing and the scope of the clinical testing that may be required by regulatory authorities for its molecular chaperone co-induction drug candidates, including arimoclomol, and other products, and the timing and outcomes of those tests, uncertainties related to the early stage of CytRx’s diabetes, obesity, cytomegalovirus and ALS research, the need for future clinical testing of any RNAi-based products and small molecules that may be developed by CytRx, the significant time and expense that will be incurred in developing any of the potential commercial applications for CytRx’s RNAi technology or small molecules, CytRx’s need for additional capital to fund its ongoing working capital needs, including ongoing research and development expenses related to its molecular chaperone co-induction drug candidates, risks relating to the enforceability of any patents covering CytRx’s products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for CytRx’s products. Additional uncertainties and risks are described in CytRx’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For Additional Information: CytRx Corporation: CEOcast, Inc. Ed Umali (eumali@cytrx.com) Investor Contacts: Director of Corporate Communications Kevin Theiss (310) 826-5648, ext. 309 (ktheiss@ceocast.com) Cormac Glynn (cglynn@ceocast.com) (212) 732-4300

CytRx Corporation

CONTACT: Ed Umali, Director of Corporate Communications of CytRxCorporation, +1-310-826-5648, ext. 309, eumali@cytrx.com; or Investors,Kevin Theiss, ktheiss@ceocast.com, or Cormac Glynn, cglynn@ceocast.com,both of CEOcast, Inc., +1-212-732-4300, for CytRx Corporation

MORE ON THIS TOPIC